Dose response to a single intramuscular injection of recombinant adeno- associated virus-erythropoietin in monkeys

Steven M. Rudich, Shangzhen Zhou, Ranjana Srivastava, Jaime A. Escobedo, Richard V Perez, William C. Manning

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Background. Anemia is a significant problem in many disease states. Erythropoietin (Epo) has been used in the treatment of anemia associated with numerous chronic diseases. This study investigates the dose-response profiles of a single intramuscular (im) injection of a recombinant adeno-associated virus vector (rAAV) containing the Epo gene with the goal of achieving a sustained elevation of hematocrit (Hct). Methods. Cynomolgus (cm) monkeys were given single injections of different doses of rAAV-cm-Epo. The biological effect of Epo gene expression was monitored by determining the Hct levels and circulating hormone levels by ELISA. Antibody to the rAAV capsid protein was also measured over the 41-week period of the experiment. Results. Epo expression was noted only when 2 x 1011 or more particles were injected. Epo was noted to be increased as soon as 1 week postinjection and was maximum in 6 to 8 weeks. This level of expression remained constant for nearly 20 weeks. Animals given the highest dose of rAAV developed a higher Hct over the first 8 weeks postinjection than those given an intermediate dose. However, the maximum levels of hemoglobin were the same. There was a weak correlation between amount of rAAV injected and capsid antibody response. Conclusions. AAV vectors are able to transduce skeletal muscle and are capable of achieving sustained expression and systemic delivery of a therapeutic protein following a single in administration. Dose responses to rAAV-Epo are achievable, although a threshold inoculum of virus is necessary to produce an effect and the therapeutic window is narrow. (C) 2000 Academic Press.

Original languageEnglish (US)
Pages (from-to)102-108
Number of pages7
JournalJournal of Surgical Research
Volume90
Issue number2
DOIs
StatePublished - May 15 2000

Fingerprint

Dependovirus
Intramuscular Injections
Erythropoietin
Haplorhini
Hematocrit
Anemia
Macaca fascicularis
Capsid
Capsid Proteins
Therapeutic Uses
Antibody Formation
Hemoglobins
Skeletal Muscle
Chronic Disease
Enzyme-Linked Immunosorbent Assay
Hormones
Viruses
Gene Expression
Injections
Antibodies

Keywords

  • Adeno-associated virus vector
  • Cynomolgus monkeys
  • Erythropoietin
  • Gene therapy

ASJC Scopus subject areas

  • Surgery

Cite this

Dose response to a single intramuscular injection of recombinant adeno- associated virus-erythropoietin in monkeys. / Rudich, Steven M.; Zhou, Shangzhen; Srivastava, Ranjana; Escobedo, Jaime A.; Perez, Richard V; Manning, William C.

In: Journal of Surgical Research, Vol. 90, No. 2, 15.05.2000, p. 102-108.

Research output: Contribution to journalArticle

Rudich, Steven M. ; Zhou, Shangzhen ; Srivastava, Ranjana ; Escobedo, Jaime A. ; Perez, Richard V ; Manning, William C. / Dose response to a single intramuscular injection of recombinant adeno- associated virus-erythropoietin in monkeys. In: Journal of Surgical Research. 2000 ; Vol. 90, No. 2. pp. 102-108.
@article{9772e2610fb74b9c93e472a2abeb37e8,
title = "Dose response to a single intramuscular injection of recombinant adeno- associated virus-erythropoietin in monkeys",
abstract = "Background. Anemia is a significant problem in many disease states. Erythropoietin (Epo) has been used in the treatment of anemia associated with numerous chronic diseases. This study investigates the dose-response profiles of a single intramuscular (im) injection of a recombinant adeno-associated virus vector (rAAV) containing the Epo gene with the goal of achieving a sustained elevation of hematocrit (Hct). Methods. Cynomolgus (cm) monkeys were given single injections of different doses of rAAV-cm-Epo. The biological effect of Epo gene expression was monitored by determining the Hct levels and circulating hormone levels by ELISA. Antibody to the rAAV capsid protein was also measured over the 41-week period of the experiment. Results. Epo expression was noted only when 2 x 1011 or more particles were injected. Epo was noted to be increased as soon as 1 week postinjection and was maximum in 6 to 8 weeks. This level of expression remained constant for nearly 20 weeks. Animals given the highest dose of rAAV developed a higher Hct over the first 8 weeks postinjection than those given an intermediate dose. However, the maximum levels of hemoglobin were the same. There was a weak correlation between amount of rAAV injected and capsid antibody response. Conclusions. AAV vectors are able to transduce skeletal muscle and are capable of achieving sustained expression and systemic delivery of a therapeutic protein following a single in administration. Dose responses to rAAV-Epo are achievable, although a threshold inoculum of virus is necessary to produce an effect and the therapeutic window is narrow. (C) 2000 Academic Press.",
keywords = "Adeno-associated virus vector, Cynomolgus monkeys, Erythropoietin, Gene therapy",
author = "Rudich, {Steven M.} and Shangzhen Zhou and Ranjana Srivastava and Escobedo, {Jaime A.} and Perez, {Richard V} and Manning, {William C.}",
year = "2000",
month = "5",
day = "15",
doi = "10.1006/jsre.2000.5859",
language = "English (US)",
volume = "90",
pages = "102--108",
journal = "Journal of Surgical Research",
issn = "0022-4804",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - Dose response to a single intramuscular injection of recombinant adeno- associated virus-erythropoietin in monkeys

AU - Rudich, Steven M.

AU - Zhou, Shangzhen

AU - Srivastava, Ranjana

AU - Escobedo, Jaime A.

AU - Perez, Richard V

AU - Manning, William C.

PY - 2000/5/15

Y1 - 2000/5/15

N2 - Background. Anemia is a significant problem in many disease states. Erythropoietin (Epo) has been used in the treatment of anemia associated with numerous chronic diseases. This study investigates the dose-response profiles of a single intramuscular (im) injection of a recombinant adeno-associated virus vector (rAAV) containing the Epo gene with the goal of achieving a sustained elevation of hematocrit (Hct). Methods. Cynomolgus (cm) monkeys were given single injections of different doses of rAAV-cm-Epo. The biological effect of Epo gene expression was monitored by determining the Hct levels and circulating hormone levels by ELISA. Antibody to the rAAV capsid protein was also measured over the 41-week period of the experiment. Results. Epo expression was noted only when 2 x 1011 or more particles were injected. Epo was noted to be increased as soon as 1 week postinjection and was maximum in 6 to 8 weeks. This level of expression remained constant for nearly 20 weeks. Animals given the highest dose of rAAV developed a higher Hct over the first 8 weeks postinjection than those given an intermediate dose. However, the maximum levels of hemoglobin were the same. There was a weak correlation between amount of rAAV injected and capsid antibody response. Conclusions. AAV vectors are able to transduce skeletal muscle and are capable of achieving sustained expression and systemic delivery of a therapeutic protein following a single in administration. Dose responses to rAAV-Epo are achievable, although a threshold inoculum of virus is necessary to produce an effect and the therapeutic window is narrow. (C) 2000 Academic Press.

AB - Background. Anemia is a significant problem in many disease states. Erythropoietin (Epo) has been used in the treatment of anemia associated with numerous chronic diseases. This study investigates the dose-response profiles of a single intramuscular (im) injection of a recombinant adeno-associated virus vector (rAAV) containing the Epo gene with the goal of achieving a sustained elevation of hematocrit (Hct). Methods. Cynomolgus (cm) monkeys were given single injections of different doses of rAAV-cm-Epo. The biological effect of Epo gene expression was monitored by determining the Hct levels and circulating hormone levels by ELISA. Antibody to the rAAV capsid protein was also measured over the 41-week period of the experiment. Results. Epo expression was noted only when 2 x 1011 or more particles were injected. Epo was noted to be increased as soon as 1 week postinjection and was maximum in 6 to 8 weeks. This level of expression remained constant for nearly 20 weeks. Animals given the highest dose of rAAV developed a higher Hct over the first 8 weeks postinjection than those given an intermediate dose. However, the maximum levels of hemoglobin were the same. There was a weak correlation between amount of rAAV injected and capsid antibody response. Conclusions. AAV vectors are able to transduce skeletal muscle and are capable of achieving sustained expression and systemic delivery of a therapeutic protein following a single in administration. Dose responses to rAAV-Epo are achievable, although a threshold inoculum of virus is necessary to produce an effect and the therapeutic window is narrow. (C) 2000 Academic Press.

KW - Adeno-associated virus vector

KW - Cynomolgus monkeys

KW - Erythropoietin

KW - Gene therapy

UR - http://www.scopus.com/inward/record.url?scp=0034657760&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034657760&partnerID=8YFLogxK

U2 - 10.1006/jsre.2000.5859

DO - 10.1006/jsre.2000.5859

M3 - Article

VL - 90

SP - 102

EP - 108

JO - Journal of Surgical Research

JF - Journal of Surgical Research

SN - 0022-4804

IS - 2

ER -